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Cherubism, a case of bone remodeling gone haywire, is associated with mutations in the adaptor
protein SH3BP2. Two papers in this issue of Cell (Guettler et al. and Levaot et al.) demonstrate
that these mutations disrupt the interaction between SH3BP2 and Tankyrase and describe rules
for substrate recognition by this poly(ADP-ribose) polymerase. Establishing such rules paves the
way to identifying all Tankyrase-regulated pathways in cells.Studies of rare genetic diseases have
frequently opened doors to an under-
standing of fundamental cellular mecha-
nisms. Two articles in the current issue
of Cell (Guettler et al., 2011; Levaot
et al., 2011) highlight cherubism as an
intriguing example. Cherubism is a domi-
nantly inherited syndrome characterized
by progressive loss of bone in the jaws
and accumulation of inflammatory/fibrous
tissue in the lower face. These studies
provide molecular insight into the etiology
of this disease, revealing a role for the
poly(ADP-ribose) polymerase Tankyrase
in normal bone homeostasis and pro-
viding important inroads toward the
understanding of Tankyrase functions.
A breakthrough in understanding the
cause of cherubism was the identifica-
tion of mutations in the SH3-binding
protein SH3BP2 (Cicchetti et al., 1992) in
several cherubism families (Ueki et al.,
2001). Curiously, all mutations were mis-
sense mutations within a hexapeptide
sequence, RSPPDG, located between
the N-terminal pleckstrin homology do-
main and C-terminal SH2 domain of
SH3BP2 (see Figure 1). Genetic consider-
ations suggested that the mutations were
unlikely to represent loss-of-function mu-
tations (Ueki et al., 2001), and Ueki et al.
(2007) found that homozygous mutants
carrying the most common mutation, a
proline-to-arginine substitution (P418R
in humans; P416R in mice) knocked
into the mouse Sh3bp2 gene, exhibited
major hallmarks of cherubism after birth:
bone loss, enhanced osteoclast differ-
entiation, and systemic inflammation.
The SH3BP2 mutation caused enhanced1222 Cell 147, December 9, 2011 ª2011 ElseERK1/2-mediated TNF-a expression in
macrophages and increased levels of
SYK activation in osteoclasts in vitro.
Overexpression of wild-type SH3BP2 had
the same effects, indicating that cherub-
ism mutations represent gain of SH3BP2
function. TNF-a appeared crucial for the
homozygous phenotype as its absence
resulted in rescue of inflammation and
a major portion of the bone loss. Finally,
bone marrow transplantation experiments
provided evidence that cherubism, de-
spite its jaw-restricted phenotype in hu-
mans, is primarily a disorder of myeloid
cells.
These studies provided significant
insights into the pathogenesis of cherub-
ism, but important questions were left un-
answered, including the question of how
sequence changes within the RSPPDG
motif increase SH3BP2 function. In this
issue of Cell, Levaot et al. (2011) and
Guettler et al. (2011) provide the answer:
Cherubism mutations abolish recogni-
tion of SH3BP2 by Tankyrase (TNKS/
TNKS2) (Hsiao and Smith, 2008; Smith
et al., 1998), resulting in increased sta-
bility and levels of SH3BP2 and hyperacti-
vation of SRC, SYK, and VAV pathways.
Levaot et al. (2011) show that SH3BP2
binds to TNKS2 via the RSPPDG motif;
TNKS2-mediated PARsylation of SH3BP2
targets it for ubiquitylation by the E3-
ubiquitin ligase RNF146 and subsequent
degradation.
Levaot et al. (2011) found that mono-
cytes isolated from Tnks2-deficient mice
showed rates of osteoclast formation
that were intermediate between rates ob-
tained with control and homozygousvier Inc.cherubism macrophages. Furthermore,
monocytes depleted for both TNKS and
TNKS2 or RNF146 showed enhanced
osteoclast formation, high levels of SRC,
SYK, and VAV phosphorylation, and in-
creased levels of SH3BP2, similar to the
osteoclast phenotype in cells harboring
the homozygous P416R cherubism muta-
tion in SH3BP2. Poly(ADP-ribose) poly-
merase (PARP) inhibitorsenhancedosteo-
clastogenesis in an SH3BP2-dependent
manner, and wild-type macrophages
treated with PARP inhibitor showed in-
creased levels of TNF-a secretion com-
pared with control cells, similar to macro-
phages harboring the P416R cherubism
mutation. Hyperactivation of osteoclasts
mediated by stabilized SH3BP2 could be
completely antagonized by inhibition of
SRC. Combined with the finding that lack
of TNF-a in homozygous cherubism mice
results in rescue of the inflammatory and
major bone loss phenotypes (Ueki et al.,
2007), thedata suggest that a combination
of anti-TNF-a antibody and SRC inhibitors
may be effective in the treatment of
cherubism.
Elegant and definitive structural evi-
dence that dysregulation of substrate
recognition by Tankyrase is indeed the
underlying mechanistic basis of cherub-
ism is provided by Guettler et al. (2011).
The authors also use the cherubism
case study as a starting point for defining
general sequence rules guiding recogni-
tion of all potential substrates by TNKS/
TNKS2. Using a peptide from the Tankyr-
ase-binding region of SH3BP2 in binding
assays with the entire ankyrin repeat re-
gion or individual ankyrin repeat clusters
Figure 1. Mutant SH3BP2 Escapes PARsylation by Tankyrase in Cherubism
Schematic representation of the domain structures of SH3BP2 (pleckstrin homology [PH] and SH2
domains) and Tankyrase 2 (TNKS2) (five ankyrin repeat clusters—ARCs, a sterile-alpha motif—SAM, and
a PARP catalytic domain) and their interaction via the substrate recognition sequence RSPPDG in
SH3BP2 (at left). Although RSPPDGQS was the sequence utilized by Guettler et al. (2011) for binding, only
the shorter sequence, RSPPDG, is shown in the figure because Levaot et al. (2011) demonstrated that it
was sufficient for binding. In Tankyrase, ARCs 1, 2, 4, and 5 can bind substrate recognition sequences. For
simplicity and because ARC4 was used for crystal structure analyses by Guettler et al. (2011), SH3BP2 is
shown as interacting with ARC4. In contrast to the Tankyrase-mediated PARsylation of wild-type SH3BP2,
followed by RNF146-dependent ubiquitylation and proteosomal degradation, SH3BP2 with a cherubism
mutation, such as P416R (at right), does not bind to Tankyrase. As a consequence, mutant SH3BP2
accumulates, downstream targets are hyperactivated, and osteoclast formation and TNF-a production
are increased.(ARCs), the authors confirm that there
are at least four functional substrate-
binding sites in TNKS2 (Seimiya et al.,
2004). Any of the five ARCs, except
ARC3, binds SH3BP2 control peptide
but not SH3BP2 variants with the cherub-
ism mutations R413Q or P416H. The
crystal structure of the apo form and an
SH3BP2 peptide-bound form of ARC4
indicates that an ARC contains a stack
of five ankyrin repeats, with the SH3BP2
motif RSPPDGQS binding to a pocket
formed by the central three ankyrin
repeats. Remarkably, crystal structures
of ARC4 bound to recognition peptides
from additional Tankyrase substrates re-
vealed that all substrates employ a
common binding mode despite the vari-
ability of the interaction sequence. To
obtain further insight into ARC binding
to different substrate sequences, the
authors used the SH3BP2 peptideRSPPDGQS to construct a peptide library
with each position in the sequence
exchanged with each of the 20 standard
amino acid residues. Testing the peptides
in binding assays with ARC4, the authors
show that arginine and glycine in positions
1 and 6 are critical for binding, and that
all characterized cherubism mutations
(Lietman et al., 2006; Ueki et al., 2001)
act by abolishing binding of the SH3BP2
motif to ARCs. Finally, the use of substrate
recognition rules to predict, based on an
in silico search of the human proteome,
potential Tankyrase interactors leads to
the conclusion that a wide range, possibly
hundreds, of proteins may be Tankyrase
substrates, thus raising the possibility
that Tankyrase-dependent regulation of
cellular activities may be more wide-
spread than currently recognized.
The two studies highlighted here reveal
the mechanism by which Tankyrase regu-Cell 147, Dlates SH3BP2 stability and howmutations
in cherubism, like a perfect mutagenesis
experiment of nature, disrupt this regula-
tion. However, this does not mean that
all questions associated with cherubism
have been answered. For example, it
remains unclear how the SH3BP2 muta-
tions cause defects that are primarily
restricted to the jaws in humans, or why
the phenotype regresses after puberty.
Is it possible that Tankyrase-independent
mechanisms that control SH3BP2 levels
or activity are less active in the jaws than
in other regions of the human skeleton?
Could such mechanisms become more
efficient after puberty? Are the mecha-
nisms by which SH3BP2 controls os-
teoclast formation and TNF-a levels in
macrophages positively modulated by
processes that are more active in the
growing human jaws than in other or-
gans? Given what we now know about
cherubism, it should be possible to design
systematic studies to answer these and
other questions.REFERENCES
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